OKYO
OKYO Pharma Limited NASDAQ Listed May 17, 2022$1.69
-1.17%
vs $1.71
Mkt Cap $66.7M
52w Low $1.51
10.2% of range
52w High $3.27
50d MA $1.61
200d MA $2.01
P/E (TTM)
-14.1x
EV/EBITDA
—
P/B
—
Debt/Equity
0.0x
ROE
—
P/FCF
-36.8x
RSI (14)
51.20
ATR (14)
$0.07
Beta
-0.12
50d MA
$1.61
200d MA
$2.01
Avg Volume
55.6K
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
55 Park Lane · London, X0 W1K 1NA · GB
Data updated apr 26, 2026 5:14pm
· Source: massive.com